Under construction – not a live service
Sign in

2024-520052-19-04RecruitingPhase 1/2

Research on two creams (Monobenzon / Imiquimod) together with the standard treatment for advanced or metastatic melanoma (ImMI).

Source: EU CTIS (euclinicaltrials.eu) · Last updated 13 Apr 2026

Next steps

Status (registry)
Recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
18 (estimated)
First submitted
12 Jan 2026
Start date
18 Sept 2026
Lead sponsor
Amsterdam UMC Stichting
Diseases
Melanoma
EU CT number
2024-520052-19-04

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 18
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic melanoma who will get two creams (Monobenzon and Imiquimod) together with the standard treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
Advanced or metastatic melanoma

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Amsterdam UMC StichtingAmsterdamNetherlandsRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.